<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The synthesis and pharmacological profile of a series of neuroprotective <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="4" ids="48705">agonists</z:chebi> are described </plain></SENT>
<SENT sid="1" pm="."><plain>Novel A(1) <z:chebi fb="4" ids="48705">agonists</z:chebi> with potent central <z:mp ids='MP_0008912'>nervous</z:mp> system effects and diminished influence on the cardiovascular system are reported and compared to selected reference <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The novel compounds featured are derived structurally from two key lead structures: 2-chloro-N-(1-phenoxy-2-<z:chebi fb="1" ids="26308">propyl</z:chebi>)<z:chebi fb="3" ids="16335">adenosine</z:chebi> (NNC 21-0041, 9) and 2-chloro-N-(1-piperidinyl)<z:chebi fb="3" ids="16335">adenosine</z:chebi> (NNC 90-1515, 4) </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="4" ids="48705">agonists</z:chebi> are characterized in terms of their in vitro profiles, both binding and functional, and in vivo activity in relevant animal models </plain></SENT>
<SENT sid="4" pm="."><plain>Neuroprotective properties assessed after postischemic dosing in a Mongolian gerbil severe temporary forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> paradigm, using hippocampal CA1 damage endpoints, and the efficacy of these <z:chebi fb="4" ids="48705">agonists</z:chebi> in an A(1) functional assay show similarities to some reference <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>However, the new compounds we describe exhibit diminished cardiovascular effects in both anesthetized and awake rats when compared to reference A(1) <z:chebi fb="4" ids="48705">agonists</z:chebi> such as (R)-phenylisopropyladenosine (R-PIA, 5), N-cyclopentyladenosine (CPA, 2), 4, N-[(1S,trans)-2-hydroxycyclopentyl]<z:chebi fb="3" ids="16335">adenosine</z:chebi> (GR 79236, 26), N-<z:chebi fb="0" ids="52552">cyclohexyl</z:chebi>-2'-O-methyladenosine (SDZ WAG 994, 27), and N-[(<z:chebi fb="0" ids="52554">2-methylphenyl</z:chebi>)<z:chebi fb="36" ids="29309">methyl</z:chebi>]<z:chebi fb="3" ids="16335">adenosine</z:chebi> (Metrifudil, 28) </plain></SENT>
<SENT sid="6" pm="."><plain>In mouse permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, 2-chloro-N-[(R)-[(2-benzothiazolyl)<z:chebi fb="1" ids="29830">thio</z:chebi>]-2-<z:chebi fb="1" ids="26308">propyl</z:chebi>]<z:chebi fb="3" ids="16335">adenosine</z:chebi> (NNC 21-0136, 12) exhibited significant neuroprotection at the remarkably low total intraperitoneal dose of 0.1 mg/kg, a dose at which no cardiovascular effects are observed in conscious rats </plain></SENT>
<SENT sid="7" pm="."><plain>The novel <z:chebi fb="4" ids="48705">agonists</z:chebi> described inhibit 6, 7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate-induced <z:hpo ids='HP_0001250'>seizures</z:hpo>, and in mouse locomotor activity higher doses are required to reach ED(50) values than for reference A(1) <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that two of the novel <z:chebi fb="3" ids="16335">adenosine</z:chebi> derivatives revealed herein, 12 and 5'-deoxy-5'-chloro-N-[4-(<z:chebi fb="0" ids="48499">phenylthio</z:chebi>)-1-piperidinyl]<z:chebi fb="3" ids="16335">adenosine</z:chebi> (NNC 21-0147, 13), representatives of a new series of P(1) ligands, reinforce the fact that novel selective <z:chebi fb="3" ids="16335">adenosine</z:chebi> A(1) <z:chebi fb="4" ids="48705">agonists</z:chebi> have potential in the treatment of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in humans </plain></SENT>
</text></document>